Radioactive drug targets tough lung cancers in early trial
Disease control
Ongoing
This early-phase study tests a new radioactive drug, 225Ac-ABD147, in people with small cell lung cancer or large cell neuroendocrine lung cancer that has spread and was previously treated with platinum chemotherapy. The main goals are to check safety, find the best dose, and see…
Phase: PHASE1 • Sponsor: Abdera Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC